Updated efficacy and safety of dabrafenib plus trametinib in patients with recurrent/ refractory BRAF V600E-mutated high-grade glioma (HGG) and low-grade glioma (LGG)

Authors
Category Primary study
JournalNeuro-Oncology
Year 2019
This article has no abstract
Epistemonikos ID: a25cbed9911aabaaa832717f755707e8c73f3da1
First added on: Feb 11, 2025